Of note, G6PD deficiency is further reduced by nonenzymatic glycation in states of hyperglycemia, creating a self-reinforcing loop [25], reducing endothelial nitric oxide bioavailability [26, 27] and increasing oxidative stress with activation of proinflammatory pathways in G6PD [7], eventually resulting in arterial stiffening and remodelling [28]. This evidence concerns the gene G6PD and Hyperglycemia.